Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | ClarIDHy: ivosidenib in CCA

Ghassan Abou-Alfa • 1 Jul 2020
ESMO WCGIC 2020
Bile Duct Cancer Gastrointestinal Cancer Ivosidenib Pemigatinib
ClarIDHy

Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, outlines novel targeted therapies in cholangiocarcinoma (CCA). Specifically discussed is results from the Phase III ClarIDHy study (NCT02989857), evaluating ivosidenib in IDH1-mutant, chemotherapy-refractory CCA. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ghassan Abou-Alfa

2:19
Should HCC be treated with locoregional or systemic therapies?
Ghassan Abou-Alfa • 22 Jun 2023
2:32
The role of systemic treatment in early-stage hepatocellular carcinoma
Ghassan Abou-Alfa • 22 Jun 2023
1:53
SCG101: a novel T-cell therapy in advanced hepatitis B-related HCC
Ghassan Abou-Alfa • 22 Jun 2023
3:52
What role does TIGIT inhibition have in treating hepatocellular carcinoma?
Ghassan Abou-Alfa • 22 Jun 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals